Comparing two methods for guiding heart procedures in patients with coronary artery disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The INSIGHTFUL-FFR trial is a multicenter, randomized, open-label study that aims to evaluate the clinical outcomes of using a pressure microcatheter compared to a traditional pressure wire for guiding percutaneous coronary interventions (PCI) in patients with stable coronary artery disease or stabilized acute coronary syndrome. The trial will involve patients eligible for elective PCI and will assess whether the pressure microcatheter provides non-inferior results in clinical decision-making. Participants will be randomly assigned to receive either the pressure microcatheter-guided strategy or the pressure wire-guided strategy. The study seeks to simplify the procedure while maintaining accuracy in measuring lesion severity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The subject must be at least 18 years of age and younger than 85 years old.
2. Eligible for elective PCI.
3. Stable angina or ACS (non-culprit vessels only and outside of primary intervention during acute STEMI)
4. Subject willing to participate and able to understand, read and sign the Informed Consent.

Exclusion Criteria:

1. STEMI as clinical presentation.
2. Chronic total occlusion as a target vessel.
3. Significant contraindication to adenosine administration (e.g. heart block, severe asthma)
4. Uncontrolled or recurrent ventricular tachycardia.
5. Hemodynamic instability.
6. Severe valvular disease.
7. Severe renal dysfunction defined as an eGFR ≤30 mL/min/1.73 m2.
8. Comorbidity with life expectancy ≤ 2 years.
9. Inability to take DAPT (both aspirin and a P2Y12 inhibitor) for at least 12 months in the patient presenting with an ACS, or at least six months in the patient presenting with stable CAD, unless the patient is also taking chronic oral anticoagulation in which case a shorter duration of DAPT may be prescribed per local standard of care.
10. Planned major cardiac or non-cardiac surgery within 24 months after the index procedure. Note: major surgery is any invasive procedure in which an extensive resection is performed, e.g., a body cavity is entered, organs are removed, or normal anatomy is altered. Note: minor surgery is an operation on the superficial structures of the body or a manipulative procedure that does not involve a serious risk. Planned minor surgery is not excluded.
11. Subject has known hypersensitivity or contraindication to any of the study drugs (including all P2Y12 inhibitors, one or more components of the study devices, including everolimus, zotarolimus, biolimus, sirolimus, cobalt, chromium, nickel, platinum, tungsten, acrylic, and fluoropolymers, or radiocontrast dye that cannot be adequately pre- medicated.
12. The subject has received a functioning solid organ transplant or is active on a waiting list for any solid organ transplants with expected transplantation within 24 months.
13. The subject receives immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are not included as immunosuppressant therapy.
14. The subject has previously received or is scheduled to receive radiotherapy to a coronary artery (vascular brachytherapy) or the chest/mediastinum.
15. Subject has a platelet count \<100,000 cells/mm3 or \>700,000 cells/mm3.
16. The subject has a documented or suspected hepatic disorder defined as cirrhosis or Child-Pugh ≥ Class B.
17. The subject has a history of bleeding diathesis or coagulopathy or has had a significant gastro-intestinal or significant urinary bleed within the past six months. The subject has had a cerebrovascular accident or transient ischemic neurological attack (TIA) within the past six months, any prior intracranial bleed, any permanent neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous malformation, etc. The subject has a life expectancy of \<2 years for any non-cardiac cause.
18. The subject is currently participating in another investigational drug or device clinical study.
19. Pregnancy or nursing.
20. Presence of other anatomic or comorbid conditions or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements or impact the scientific soundness of the clinical investigation results.

Where it's running

• OLV Aalst
  Aalst, Oost-Vlaanderen, Belgium Recruiting
• Universitair ziekenhuis Brussel
  Brussels, Belgium Recruiting
• Zol
  Genk, Belgium Recruiting
• CHU Lille
  Lille, France Recruiting
• Icps
  Paris, France Recruiting
• Herzzentrum Dresden
  Dresden, Germany Recruiting

Study contacts

• Principal investigator: Emanuele Barbato, MD, PhD — Azienda Ospedaliera Universitaria Sant'Andrea, Roma
• Study coordinator: Sofie Pardaens
• Email: sofiepardaens@coreaalst.com
• Phone: 0032 53 72 42 30

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-driven Medipixel fractional flow reserve to guide PCI

  This test checks whether an AI-based, angiography-derived Medipixel FFR method can guide PCI as safely and effectively as standard invasive pressure-wire FFR in adults with coronary artery disease.

  Recruiting at 23 sites Samsung Medical Center · Seoul, Select State and 22 other locations · NCT07329699

• Freesolve resorbable magnesium scaffold vs. Xience stent for up to two new heart artery lesions

  This trial tests whether the Freesolve resorbable magnesium scaffold works as well as the Xience drug-eluting stent for treating up to two new coronary artery lesions in adults.

  Recruiting at 3 sites Teleflex · Washington D.C., District of Columbia and 2 other locations · NCT07258290

• AI-assisted interpretation of chest pain CT in the emergency department

  A pragmatic randomized trial tests whether an AI tool (Angiomics) helps emergency physicians interpret coronary CT angiography in adults with acute chest pain.

  Recruiting Yonsei University · Seoul · NCT07235657

• Comparing two types of drug-coated stents for patients at high bleeding risk

  This study is testing if a new type of drug-coated stent is just as good and safe as a standard one for people with coronary artery disease who are at high risk of bleeding.

  Recruiting at 6 sites Biosensors Europe SA · Johor Bahru, Johor and 5 other locations · NCT06657326

• Single versus dual antiplatelet therapy after drug-coated balloon angioplasty in elderly or high-bleeding-risk patients

  This study tests whether taking one antiplatelet medicine is as safe and causes less bleeding than taking two medicines for people aged 75 or older, or adults at high bleeding risk, after drug-coated balloon angioplasty for coronary artery disease.

  Recruiting Fondazione Ricerca e Innovazione Cardiovascolare ETS · Milan, MI · NCT06535568

• Heart registry for patients after coronary interventions in South East Netherlands

  This study is creating a registry to help doctors better understand and treat patients in South East Netherlands who have had heart procedures, aiming to reduce their risk of future heart problems.

  Recruiting at 4 sites Radboud University Medical Center · Heerlen, Limburg and 3 other locations · NCT06512493

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.